Search for:

In brief

As the world prepares for the rollout of the COVID-19 vaccine, manufacturers, governments, and clients in the logistics sector are looking into various structures and arrangements that will help bring the vaccine to the public as soon as possible.

Our Primer focuses on key legal issues and high-level considerations on topics such as the procurement framework, regulatory approvals, and contractual stipulations relating to the supply and distribution of the COVID-19 vaccine across 14 Asia Pacific jurisdictions.


This guide has been prepared for the general information of clients and professional associates of Baker McKenzie. The content of this guide is current as of 9 February 2021. It is not legal advice and should not be regarded as a substitute for legal advice.

If you have questions or would like to discuss any of the topics raised in this Primer in more detail, please do get in touch.

Click here to download the guide.

Author

Maria Christina Macasaet-Acaban is a partner, and the head of the Corporate & Commercial Practice Group, the Healthcare Industry Group, and the Competition Focus Group, in Quisumbing Torres, a member firm of Baker & McKenzie International. She is a member of Baker & McKenzie International's Asia Pacific Healthcare Steering Committee, and the Asia Pacific Competition Steering Committee. She has 19 years of experience advising and representing multinational corporations on domestic and cross-border transactions.

Author

Yee Chung Seck leads the Firm’s Mergers & Acquisitions, IT/C, Pharmaceutical and Healthcare Practices in Vietnam. Chambers Global (2014, 2013) and Chamber Asia (from 2010 to 2015) rank him as a leading lawyer in the field of Corporate M&A and TMT in Vietnam. He is a member of the Singapore Bar Association and serves as vice president of the Singapore Business Group. He also serves as AmCham's IT/C Sub-Committee Co-Chair. Mr. Seck is fluent in English and conversational in Mandarin.

Author

Tracy Wut is the managing partner for Baker McKenzie's China and Hong Kong offices. She is experienced in mergers and acquisitions and foreign direct investments in China. She regularly acts for clients in complex cross-border transactions, in particular in the pharmaceuticals and healthcare sector, and navigates clients through various issues relating to investments in China. She has been recommended as a leading lawyer in Corporate/M&A by Chambers Global, Corporate/M&A and Life Sciences by Chambers Asia and M&A and private equity by IFLR1000. She is the co-head of the Pharmaceuticals and Healthcare Industry Group in China and Hong Kong.